Uncovering the therapeutic potential of anti-tuberculoid agent Isoniazid in a model of microbial-driven Crohn’s disease - Top-Institutions - MDSpire

Uncovering the therapeutic potential of anti-tuberculoid agent Isoniazid in a model of microbial-driven Crohn’s disease

By
Matthew Stephens
Keith Keane
Simon Roizes
Manon Defaye
Christophe Altier
Pierre-Yves von der Weid
February 23, 2025
0 min

Journal Of Crohn's And Colitis

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

#1

Mayo Clinic

Rochester, MN
Key Differentiators
- Gastroenterology
- Immunology
- Infectious Diseases
#2

Johns Hopkins University

Baltimore, MD
Key Differentiators
- Gastroenterology
- Microbiology
- Immunology
#3

Massachusetts General Hospital / Harvard Medical School

Boston, MA
Key Differentiators
- Gastroenterology
- Immunology
- Infectious Diseases
#4

University of California, San Francisco (UCSF)

San Francisco, CA
Key Differentiators
- Gastroenterology
- Microbiology
- Immunology
#5

Cleveland Clinic

Cleveland, OH
Key Differentiators
- Gastroenterology
- Infectious Diseases

Original Source(s)

Journal Of Crohn's And Colitis

Uncovering the therapeutic potential of anti-tuberculoid agent Isoniazid in a model of microbial-driven Crohn’s disease

by Matthew Stephens, Keith Keane, Simon Roizes, Manon Defaye, Christophe Altier, Pierre-Yves von der Weid
February 23, 2025

Related Content

Frontiers In Gastroenterology

GLP-1 and GLP-2 as intestinal reparative therapies in inflammatory bowel disease: mechanisms, translation, and clinical opportunity

by Joseph J. Lee, Pratikiran Bajgain, Amy L. Lightner
May 18, 2026

Conexiant

Medical Oddities: Essential Oil, Deadly Consequences

A cabinet mix-up, a chatty heart, a violet catheter bag, stressed kids, and tea that won’t save the brain—just another week.

by Teraya Smith
February 18, 2026
5 min

Bmc Gastroenterology

Exploring Comorbidity Patterns in Inflammatory Bowel Disease: Insights from the All of Us Research Program